Marta Perachino
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Marta Perachino
Jul 20, 2024, 12:56 |
Blog
Marta Perachino: Highest level science
Matteo Lambertini shared a post by Marta Perachino, Research fellow at Vall d’Hebron Institute of Oncology, on…
Jun 19, 2024, 06:40 |
Blog
Matteo Lambertini: Let’s help each others to design important academic trials
Matteo Lambertini shared on X/Twitter: "So exciting and grateful to be back at EORTC, ESMO,…
Jun 18, 2024, 04:01 |
Blog
Matteo Lambertini: Great slide to explain type I and type II errors
Matteo Lambertini recently shared a post on X: "What a great slide to explain type…
May 17, 2024, 16:02 |
Blog
Marta Perachino: Check out our systematic review and metanalysis of ADCs vs TPC for mBC
Marta Perachino, Research fellow at Vall d’Hebron Institute of Oncology, shared a post on X: "For…
Mar 22, 2024, 06:12 |
Drugs
Paolo Tarantino: We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Marta…
All:
5
Posts:
1 - 100
Michael Douglas: The Untold Story of His Battle Against Cancer
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
EMA Joins FDA: Osimerintib + Chemo Approved for EGFR-Mutated Lung Cancer
Kimryn Rathmell: Principles that have kept me going as a Physician Scientist
Amazing Results! President Lynn M. Schuchter on ASCO 2024
Facebook
RSS Feed
Twitter
Linkedin
Youtube